Summary
A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2,4, 10 and 14 months, 10 subjects subsequently received an autologous bone marrow transplant with highdose chemotherapy (ABMT). Previous exposure to VIMD did not appear to predict for or prejudice the response to subsequent ABMT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonnadonna G, Santoro A (1982) Drug selection in the treatment of Hodgkin's disease. Haematol Oncol 1: 3–12
Coltman CA, Mc Daniel TM, Balcerzak SP, Morrison FS, von Hott DD (1983) Mitozantrone hydrochloride (NSC-310739) in lymphoma. Invest New Drugs 1: 65–70
Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, haurani F, Blom J, Spurr CL Glidewell OJ, Gottlieb AJ, Holland JF (1980) A new effective four drug combination of CCNU [1(2chlorethy)-3-cyclohexyl-1-nitrosea] (NSC-79038), vinblastine, prednisone and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 46i: 654–662
Dady PJ, McElwain TJ, Austin DE, Barrett A, Peckham MJ (1982) Five years experience with ChlVPP: effective low toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45: 851–859
Jagannath S, Dicke KA, Armitage JD, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104: 163–168
Klimo P, Connors JM (1985) MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3: 1174–1182
Santoro A, Viviani S, Bonfante V, Valagussa P, Bonnadonna G (1987) Results with salvage CEP in Hodgkin's disease (HD) resistant to MOPP and ABVD. Proceedings, ECCO-4. vol 272. Artes Graf Danubio, Madrid, p 1040
Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7: 1333–1340
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Phillips, J.K., Spearing, R.L., Davies, J.M. et al. VIM-D salvage chemotherapy in Hodgkin's disease. Cancer Chemother. Pharmacol. 27, 161–163 (1990). https://doi.org/10.1007/BF00689103
Issue Date:
DOI: https://doi.org/10.1007/BF00689103